DexCom Operating Margin from 2010 to 2026
| DXCM Stock | USD 69.47 0.50 0.71% |
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 12.2 M, Other Operating Expenses of 4.1 B or Operating Income of 724.5 M, as well as many indicators such as Price To Sales Ratio of 8.52, Dividend Yield of 0.0 or PTB Ratio of 10.1. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Operating Margin | Build AI portfolio with DexCom Stock |
Evaluating DexCom's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into DexCom Inc's fundamental strength.
Latest DexCom's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of DexCom Inc over the last few years. It is DexCom's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.20 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
DexCom Operating Margin Regression Statistics
| Arithmetic Mean | (1.39) | |
| Coefficient Of Variation | (397.35) | |
| Mean Deviation | 2.51 | |
| Median | (0.06) | |
| Standard Deviation | 5.51 | |
| Sample Variance | 30.31 | |
| Range | 22.8953 | |
| R-Value | 0.44 | |
| Mean Square Error | 26.04 | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | 0.48 | |
| Total Sum of Squares | 484.95 |
DexCom Operating Margin History
About DexCom Financial Statements
DexCom investors utilize fundamental indicators, such as Operating Margin, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of DexCom Correlation against competitors. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.